Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Measles vaccine virus (MeV) is a negative-stranded RNA virus belonging to the paramyxovirus group, known for its excellent safety record as a vaccine for over 50 years. It is being investigated as an oncolytic virus (OV) for cancer therapy, particularly for pancreatic cancer. As an oncolytic virus, MeV selectively infects, replicates within, and lyses tumor cells, especially those with impaired anti-viral interferon pathways, leading to subsequent waves of oncolytic tumor cell death and induction of a profound systemic anti-tumoral immune response. Specific recombinant versions, such as MeV-SCD (suicide gene-armed vector) and MeV-GFP (carrying a green fluorescent marker protein), have been generated from original vaccine batches for research purposes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on measles vaccine virus.